

## JOINT COMPANY SECRETARY APPOINTMENT

### PERTH, Australia and SAN FRANCISCO, California – 15 June 2026

PYC advises that Mr Stephen Ledger and Mr Jonathan Riley have been appointed as joint Company Secretaries of the Company effective 15 June 2026.

Mr Ledger is an experienced Company Secretary who holds a Bachelor of Commerce from the University of Western Australia. He currently serves as a Non-Executive Director for Bertling Logistics Australia and ArcelorMittal Projects Australia, and is Founder and Executive Director of Ledger Financial Group.

Mr Riley is an experienced legal counsel who holds a Bachelor of Laws and Bachelor of Science (Pharmacology) from the University of Western Australia. Prior to joining PYC, Mr Riley held a senior legal role at CSL Limited (ASX: CSL) in Melbourne.

For the purposes of ASX Listing Rule 12.6, Mr Ledger will be responsible for communications with ASX in relation to Listing Rule matters.

Mr Daniel Coletta has resigned as Company Secretary effective 15 June 2026.

### About PYC Therapeutics

PYC Therapeutics (ASX:PYC) is a clinical-stage biotechnology company creating a new generation of RNA therapies to change the lives of patients with genetic diseases. The Company utilises its proprietary drug delivery platform to enhance the potency of precision medicines within the rapidly growing and commercially proven RNA therapeutic class. PYC's drug development programs target monogenic diseases – the indications with the highest likelihood of success in clinical development.

For more information, visit [pyctx.com](https://pyctx.com), or follow us on [LinkedIn](#).

## Forward looking statements

*Any forward-looking statements in this ASX announcement have been prepared on the basis of a number of assumptions which may prove incorrect and the current intentions, plans, expectations, and beliefs about future events are subject to risks, uncertainties and other factors, many of which are outside the Company's control. Important factors that could cause actual results to differ materially from assumptions or expectations expressed or implied in this ASX announcement include known and unknown risks. Because actual results could differ materially to assumptions made and the Company's current intentions, plans, expectations, and beliefs about the future, you are urged to view all forward-looking statements contained in this ASX announcement with caution. The Company undertakes no obligation to publicly update any forward-looking statement whether as a result of new information, future events or otherwise.*

*This ASX announcement should not be relied on as a recommendation or forecast by the Company. Nothing in this ASX announcement should be construed as either an offer to sell or a solicitation of an offer to buy or sell shares in any jurisdiction.*

*This ASX announcement was approved and authorised for release by the Board of PYC Therapeutics Limited*

### CONTACT US

**Investor relations and media contact**

[investor@pyctx.com](mailto:investor@pyctx.com)

